vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Donnelley Financial Solutions, Inc. (DFIN). Click either name above to swap in a different company.
Amphastar Pharmaceuticals, Inc. is the larger business by last-quarter revenue ($183.1M vs $172.5M, roughly 1.1× Donnelley Financial Solutions, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 3.6%, a 9.7% gap on every dollar of revenue. On growth, Donnelley Financial Solutions, Inc. posted the faster year-over-year revenue change (10.4% vs -1.8%). Donnelley Financial Solutions, Inc. produced more free cash flow last quarter ($47.9M vs $24.6M). Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs -7.9%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Donnelley Financial Solutions (DFIN) is a financial compliance company based in Chicago, Illinois, United States. The company provides software as a service (SaaS) products, software-enabled services (SeS), print, and compliance services related to US Securities and Exchange Commission regulations to companies in capital and investment markets.
AMPH vs DFIN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $172.5M |
| Net Profit | $24.4M | $6.2M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | 8.3% |
| Net Margin | 13.3% | 3.6% |
| Revenue YoY | -1.8% | 10.4% |
| Net Profit YoY | -35.7% | -1.6% |
| EPS (diluted) | $0.51 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $172.5M | ||
| Q3 25 | $191.8M | $175.3M | ||
| Q2 25 | $174.4M | $218.1M | ||
| Q1 25 | $170.5M | $201.1M | ||
| Q4 24 | $186.5M | $156.3M | ||
| Q3 24 | $191.2M | $179.5M | ||
| Q2 24 | $182.4M | $242.7M | ||
| Q1 24 | $171.8M | $203.4M |
| Q4 25 | $24.4M | $6.2M | ||
| Q3 25 | $17.4M | $-40.9M | ||
| Q2 25 | $31.0M | $36.1M | ||
| Q1 25 | $25.3M | $31.0M | ||
| Q4 24 | $38.0M | $6.3M | ||
| Q3 24 | $40.4M | $8.7M | ||
| Q2 24 | $37.9M | $44.1M | ||
| Q1 24 | $43.2M | $33.3M |
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — | ||
| Q1 24 | 52.4% | — |
| Q4 25 | 19.4% | 8.3% | ||
| Q3 25 | 13.2% | 16.1% | ||
| Q2 25 | 24.2% | 24.2% | ||
| Q1 25 | 21.9% | 22.8% | ||
| Q4 24 | 24.2% | 6.0% | ||
| Q3 24 | 29.8% | 10.1% | ||
| Q2 24 | 30.3% | 26.6% | ||
| Q1 24 | 27.9% | 21.9% |
| Q4 25 | 13.3% | 3.6% | ||
| Q3 25 | 9.0% | -23.3% | ||
| Q2 25 | 17.8% | 16.6% | ||
| Q1 25 | 14.8% | 15.4% | ||
| Q4 24 | 20.4% | 4.0% | ||
| Q3 24 | 21.1% | 4.8% | ||
| Q2 24 | 20.8% | 18.2% | ||
| Q1 24 | 25.1% | 16.4% |
| Q4 25 | $0.51 | $0.31 | ||
| Q3 25 | $0.37 | $-1.49 | ||
| Q2 25 | $0.64 | $1.28 | ||
| Q1 25 | $0.51 | $1.05 | ||
| Q4 24 | $0.74 | $0.21 | ||
| Q3 24 | $0.78 | $0.29 | ||
| Q2 24 | $0.73 | $1.47 | ||
| Q1 24 | $0.81 | $1.09 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $24.5M |
| Total DebtLower is stronger | $608.7M | $171.3M |
| Stockholders' EquityBook value | $788.8M | $379.2M |
| Total Assets | $1.6B | $800.4M |
| Debt / EquityLower = less leverage | 0.77× | 0.45× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $24.5M | ||
| Q3 25 | $276.2M | $22.7M | ||
| Q2 25 | $231.8M | $33.8M | ||
| Q1 25 | $236.9M | $16.2M | ||
| Q4 24 | $221.6M | $57.3M | ||
| Q3 24 | $250.5M | $33.6M | ||
| Q2 24 | $217.8M | $35.0M | ||
| Q1 24 | $289.6M | $43.7M |
| Q4 25 | $608.7M | $171.3M | ||
| Q3 25 | $608.6M | $154.7M | ||
| Q2 25 | $607.7M | $190.1M | ||
| Q1 25 | $603.9M | $189.5M | ||
| Q4 24 | $601.6M | $124.7M | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
| Q4 25 | $788.8M | $379.2M | ||
| Q3 25 | $776.7M | $423.1M | ||
| Q2 25 | $757.5M | $432.1M | ||
| Q1 25 | $751.3M | $419.9M | ||
| Q4 24 | $732.3M | $436.1M | ||
| Q3 24 | $727.7M | $444.5M | ||
| Q2 24 | $713.3M | $441.5M | ||
| Q1 24 | $672.4M | $408.9M |
| Q4 25 | $1.6B | $800.4M | ||
| Q3 25 | $1.7B | $816.3M | ||
| Q2 25 | $1.6B | $874.7M | ||
| Q1 25 | $1.6B | $852.8M | ||
| Q4 24 | $1.6B | $841.6M | ||
| Q3 24 | $1.5B | $843.6M | ||
| Q2 24 | $1.5B | $882.9M | ||
| Q1 24 | $1.6B | $867.8M |
| Q4 25 | 0.77× | 0.45× | ||
| Q3 25 | 0.78× | 0.37× | ||
| Q2 25 | 0.80× | 0.44× | ||
| Q1 25 | 0.80× | 0.45× | ||
| Q4 24 | 0.82× | 0.29× | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $59.8M |
| Free Cash FlowOCF − Capex | $24.6M | $47.9M |
| FCF MarginFCF / Revenue | 13.4% | 27.8% |
| Capex IntensityCapex / Revenue | 4.5% | 6.9% |
| Cash ConversionOCF / Net Profit | 1.35× | 9.65× |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $107.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $59.8M | ||
| Q3 25 | $52.6M | $74.4M | ||
| Q2 25 | $35.6M | $68.4M | ||
| Q1 25 | $35.1M | $-37.7M | ||
| Q4 24 | $29.0M | $56.4M | ||
| Q3 24 | $60.0M | $86.4M | ||
| Q2 24 | $69.1M | $56.2M | ||
| Q1 24 | $55.3M | $-27.9M |
| Q4 25 | $24.6M | $47.9M | ||
| Q3 25 | $47.2M | $59.2M | ||
| Q2 25 | $25.0M | $51.7M | ||
| Q1 25 | $24.4M | $-51.0M | ||
| Q4 24 | $16.6M | $41.3M | ||
| Q3 24 | $46.2M | $67.3M | ||
| Q2 24 | $63.1M | $36.8M | ||
| Q1 24 | $46.5M | $-40.2M |
| Q4 25 | 13.4% | 27.8% | ||
| Q3 25 | 24.6% | 33.8% | ||
| Q2 25 | 14.3% | 23.7% | ||
| Q1 25 | 14.3% | -25.4% | ||
| Q4 24 | 8.9% | 26.4% | ||
| Q3 24 | 24.1% | 37.5% | ||
| Q2 24 | 34.6% | 15.2% | ||
| Q1 24 | 27.1% | -19.8% |
| Q4 25 | 4.5% | 6.9% | ||
| Q3 25 | 2.8% | 8.7% | ||
| Q2 25 | 6.1% | 7.7% | ||
| Q1 25 | 6.3% | 6.6% | ||
| Q4 24 | 6.7% | 9.7% | ||
| Q3 24 | 7.2% | 10.6% | ||
| Q2 24 | 3.3% | 8.0% | ||
| Q1 24 | 5.1% | 6.0% |
| Q4 25 | 1.35× | 9.65× | ||
| Q3 25 | 3.03× | — | ||
| Q2 25 | 1.15× | 1.89× | ||
| Q1 25 | 1.39× | -1.22× | ||
| Q4 24 | 0.76× | 8.95× | ||
| Q3 24 | 1.48× | 9.93× | ||
| Q2 24 | 1.82× | 1.27× | ||
| Q1 24 | 1.28× | -0.84× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
DFIN
| Technology Service | $68.0M | 39% |
| Capital Markets Compliance And Communications Management | $61.6M | 36% |
| Investment Companies Software Solutions | $30.9M | 18% |
| Print And Distribution Service | $13.6M | 8% |
